Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY)

Core Insights - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is recognized as a promising growth stock by analysts, with a Buy rating reiterated by Truist Financial on October 24 [1] - The company reported strong Q3 2025 performance for its WAKIX product, generating approximately $239 million in revenue, marking a 29% year-over-year growth [2] - The increase in revenue was attributed to a record rise in the average number of patients, which grew by 500 to reach 8,100 during the quarter [2] - Harmony has also raised its revenue guidance for 2025 to a range of $845 million to $865 million, up from the previous range of $820 million to $860 million [3] - The company focuses on developing and commercializing therapies for rare neurological diseases and other unmet medical needs [3]